Hubei Biocause Pharmaceutical Co., Ltd. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
Dec'18
No of Months
12
12
12
12
12
12
Profit Before Tax
-1,972.00
-131.00
-65.00
2,682.00
3,484.00
2,487.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
15,229.00
16,381.00
12,883.00
30,405.00
35,348.00
20,737.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
13,368.00
15,093.00
13,369.00
30,573.00
37,817.00
22,357.00
Cash Flow from Investing Activities
-7,456.00
-23,184.00
-24,480.00
-16,834.00
-44,259.00
-11,876.00
Cash Flow from Financing Activities
-4,096.00
11,077.00
7,519.00
172.00
1,123.00
-3,334.00
Net Cash Inflow / Outflow
1,836.00
3,059.00
-3,606.00
13,877.00
-5,320.00
7,148.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
20.00
72.00
-15.00
-33.00
-1.00
1.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in CNY Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Hubei Biocause Pharmaceutical Co., Ltd.
Figures in Million
No Consolidated Results Declared by Selected Peer
Cash Flow - Snapshot (Consolidated) - Dec'23
YoY Growth in year ended Dec 2023 is -11.43% vs 12.90% in Dec 2022
Dec'23
Dec'22
Change(%)
Cash Flow from Operating Activities
13,368.30
15,093.59
-11.43%






